A Phase 3 interventional study of Ranibizumab 0.3 mg - 3 times monthly, then quarterly and Ranibizumab 0.5 mg - 3 times monthly, then quarterly in Age Related Macular Degeneration, sponsored by Novartis. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-03-16.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 23rd largest by enrollment of the 124 interventional ones that give a count, is one of 5 that started in 2005, is one of 31 in phase 3, and was the 7th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 353 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 10th largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2005, is one of 23 in phase 3, and was the 4th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly
Drug: Ranibizumab 0.5 mg - 3 times monthly, then quarterly
Drug: Ranibizumab 0.3 mg monthly
Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12
Visual acuity (VA) was assessed in both eyes at each study visit using best correction determined from protocol refraction. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.
Time frame: Baseline to Month 12
Mean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12
Fluorescein angiography was conducted in conjunction with color fundus photography at screening and at Months 6 and 12. Investigators used digital fluorescein angiograms to determine presence or absence of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Time frame: Baseline to Month 12
Mean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12
Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.
Time frame: Baseline to Month 12
Mean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12
Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.
Time frame: Baseline to Month 12
| Milestone | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly |
|---|---|---|---|
| Started | 120 | 118 | 115 |
| Completed | 106 | 95 | 103 |
| Not completed | 14 | 23 | 12 |
| Withdrew: Adverse event | 4 | 12 | 5 |
| Withdrew: Administrative problems | 3 | 4 | 4 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Death | 0 | 2 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 |
| Withdrew: Protocol violation | 5 | 1 | 0 |
Visual acuity (VA) was assessed in both eyes at each study visit using best correction determined from protocol refraction. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.
| letters | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly |
|---|---|---|---|
| Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12 | 4.9 ± 13.13 | 3.8 ± 13.33 | 8.3 ± 11.31 |
Fluorescein angiography was conducted in conjunction with color fundus photography at screening and at Months 6 and 12. Investigators used digital fluorescein angiograms to determine presence or absence of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
| mm^2 | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly |
|---|---|---|---|
| Mean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12 | -0.21 ± 5.616 | -1.51 ± 4.802 | -1.28 ± 4.367 |
Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.
| micrometers | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly |
|---|---|---|---|
| Mean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12 | -96.0 ± 96.82 | -105.6 ± 128.98 | -105.3 ± 128.55 |
Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.
| Micrometers | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly |
|---|---|---|---|
| Mean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12 | -93.3 ± 100.88 | -97.5 ± 117.52 | -97.9 ± 112.47 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | — | 15/120 (12.5%) | 66/120 (55%) |
| Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | — | 23/118 (19.5%) | 71/118 (60.2%) |
| Ranibizumab 0.3 mg Monthly | — | 20/115 (17.4%) | 64/115 (55.7%) |
| Event | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly |
|---|---|---|---|
| Cardiac failureCardiac disorders | 3/120 | 0/118 | 1/115 |
| Atrial fibrillationCardiac disorders | 0/120 | 2/118 | 2/115 |
| PneumoniaInfections and infestations | 1/120 | 0/118 | 2/115 |
| Atrial flutterCardiac disorders | 0/120 | 2/118 | 0/115 |
| Retinal pigment epithelial tear (Study eye)Eye disorders | 0/120 | 2/118 | 0/115 |
| AnaemiaBlood and lymphatic system disorders | 0/120 | 0/118 | 1/115 |
| Angina pectorisCardiac disorders | 0/120 | 0/118 | 1/115 |
| Myocardial infarctionCardiac disorders | 1/120 | 0/118 | 1/115 |
| Ventricular tachycardiaCardiac disorders | 0/120 | 0/118 | 1/115 |
| DysphagiaGastrointestinal disorders | 0/120 | 0/118 | 1/115 |
| Event | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly |
|---|---|---|---|
| Eye pain (Study eye)Eye disorders | 22/120 | 14/118 | 24/115 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 23/120 | 19/118 | 12/115 |
| Visual acuity reduced (Study eye)Eye disorders | 15/120 | 19/118 | 9/115 |
| Intraocular pressure increased (Study eye)Investigations | 6/120 | 7/118 | 17/115 |
| NasopharyngitisInfections and infestations | 11/120 | 4/118 | 8/115 |
| Ocular hyperaemia (Study eye)Eye disorders | 8/120 | 10/118 | 7/115 |
| HypertensionVascular disorders | 10/120 | 6/118 | 8/115 |
| Vitreous floaters (Study eye)Eye disorders | 6/120 | 6/118 | 8/115 |
| Retinal haemorrhage (Study eye)Eye disorders | 4/120 | 8/118 | 2/115 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/120 | 3/118 | 7/115 |
| Age, Customized(Participants) | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly | Total |
|---|---|---|---|---|
| 50 - < 65 | 13 | 12 | 10 | 35 |
| 65 - < 75 | 37 | 28 | 45 | 110 |
| 75 - < 85 | 61 | 72 | 46 | 179 |
| ≥ 85 | 9 | 6 | 14 | 29 |
| Sex: Female, Male(Participants) | Ranibizumab 0.3 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.5 mg - 3 Times Monthly, Then Quarterly | Ranibizumab 0.3 mg Monthly | Total |
|---|---|---|---|---|
| Female | 70 | 73 | 66 | 209 |
| Male | 50 | 45 | 49 | 144 |
The record gives a start of Dec 2005, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab